Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is reporting additional results from its human clinical study HYPER-H21-2. The study was designed to evaluate the company’s proprietary DehydraTECH(TM)-processed cannabidiol (“CBD”) and its effectiveness in the treatment of hypertension. Results confirm the substance’s ability to reduce arterial stiffness and indicate potential broader applications beyond hypertension, including the treatment of cardiovascular and other diseases. According to the company, arterial stiffness can be a predictor of a variety of human diseases, including hypertension, diabetes mellitus, renal disease and more. A unique CBD formulation developed by Lexaria, DehydraTECH-CBD is based on the company’s patented and proprietary DehydraTECH drug-delivery technology. The company’s Human Study HYPER-H21-2 included 16 human volunteers aged 45 to 65 who received either a placebo or three separate doses of DehydraTECH-CBD over a 14-hour period then observed over a 24-hour period. “Reducing arterial stiffness in Lexaria’s recent hypertension study after only a single day of dosing with our DehydraTECH-CBD is a major discovery,” said Lexaria president John Docherty in the press release. “We know that increased arterial stiffness is correlated with many serious and life-threatening diseases affecting people worldwide, and we are optimistic that our latest findings could have future widespread implications for promotion of improved human health and wellness.”
To view the full press release, visit https://ibn.fm/rZMqY
About Lexaria Bioscience Corp.
Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption of cannabinoids and nicotine by 5 to 10 times — and in some instances by as much as 27 times — compared to standard industry formulations, as well as reduce time of onset from one to two hours to minutes and mask unwanted tastes. The delivery systems are also being evaluated for orally administered, anti-viral drugs and nonsteroidal, anti-inflammatory drugs (NSAIDs) and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
